Stakeholder Opinions: Hematopoietic Stem Cell Transplantation - In need of further research and development

Published Date: April 2009 Published By: Datamonitor Page Count: 69 Order Code: R313-50617 $3,800.00   Online Download $9,500.00   Global Site License   Questions About This Report E-mail a Colleague Printable Page Fax Your Order Description Table of Contents Similar Products Introduction Hematopoietic stem cell transplantation (HSCT) has evolved considerably over the past 50 years, driven by developments in stem cell sources, donor identification and conditioning regimens. Nowadays, it has a range of applications, including the treatment of certain hematologic malignancies. However, further research efforts are required to expand its use and improve patient outcomes. Scope Usage data for HSCT and overview of the procedure in terms of stem cell donors, stem cell sources, and conditioning regimens Discussion of the use of drug therapy in HSCT conditioning and in the management of complications, including current research and development trends Unmet needs and research priorities in the field of HSCT Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and EU Highlights The use of HSCT has been increasing in the past decades, driven by developments in stem cell sources and conditioning regimens. However, it seems to remain an underutilized treatment, with many patients being referred for a transplant only at advanced stages of disease, where cure is less likely. The development of reduced-intensity conditioning (RIC) regimens is one of the major advances in the field of HSCT. Current research evaluating monoclonal antibodies and radioimmunotherapy may help increase the efficacy and specificity of conditioning therapy. The effective management of graft-versus-host disease (GVHD) is an unmet need in the field of HSCT. The availability of better preclinical models, prognostic tools, and effective therapies are considered R&D priorities. Monoclonal antibodies may have a role in the treatment of GVHD but further research is required to investigate their potential. Reasons to Purchase Obtain analysis of current HSCT usage data and trends in the use of stem cell donors, stem cell sources, and conditioning regimens Obtain an overview of current drug use in HSCT conditioning and in the management of HSCT complications, including graft-versus-host disease Identify unmet needs and research priorities in the field of HSCT Please note: this is delivered as a Zip file. Similar Products • Biotechnology Sector Published Nov 2009 by First Research, Inc. • Dealmaking and Industry Outlook: Neurological Disease Published Nov 2009 by Decision Resources • Protein Kinase Therapeutics in Oncology - Where to Commercialize? Published Oct 2009 by BioSeeker Group AB • Plunkett's Health Care Technologies Overview 2010 (Summary) Published Oct 2009 by Plunkett Research, Ltd. • The Human Genome Sequencing Center at Baylor College of Medicine Relies on Quantum's StorNext Software for Data Management Published Oct 2009 by IDC • Three Alternative Scenarios Of The Future In Vitro Diagnostics Market 2009-2018 Published Oct 2009 by Venture Planning Group • Preventive Healthcare Technologies, Products and Markets Published Oct 2009 by BCC Research • Transfection Life Science Dashboard™ Series 2 Published Oct 2009 by Percepta Associates, Inc. • Genealogy Products and Services Published Oct 2009 by Global Industry Analysts • Advances in the Use of Biomarkers in Biochip and Microarray Testing: Innovative technologies, growth opportunities and the future market outlook Published Oct 2009 by Business Insights